Trial Profile

A phase I clinical trial of SER-252

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 May 2025 According to a Serina Therapeutics media release, company is on track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinsons disease in Q4 2025
24 Mar 2025 According to a Serina Therapeutics media release, dosing of the first patient is expected in the fourth quarter 2025.
03 Feb 2025 According to a Serina Therapeutics media release, the company announced the successful closing of the second $5 million tranche of its previously announced $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform drug optimization technology, into a Phase 1 clinical trial in advanced Parkinsons disease patients in the second half of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com